Results for resistance translation from Latvian to English

krūts vēža rezistences proteīns (breast cancer resistance protein - bcrp)
breast cancer resistance protein (bcrp)

lomitapīds neinhibē krūts vēža rezistences proteīnu (breast cancer resistance protein; bcrp).
lomitapide does not inhibit breast cancer resistance protein (bcrp).

in vitro novērots, ka kobimetinibs ir vidēji stiprs bcrp (breast cancer resistance protein) inhibitors.
in vitro, cobimetinib is a moderate inhibitor of bcrp (breast cancer resistance protein).

aktīvais metabolīts ir vājš krūts vēža rezistences proteīna (breast cancer resistance protein — bcrp) substrāts.
the active metabolite is a weak substrate of the breast cancer resistance protein (bcrp).

macitentāns klīniski būtiskās koncentrācijās inhibē krūts vēža rezistences proteīnu (breast cancer resistance protein – bcrp).
macitentan inhibits the breast cancer resistance protein (bcrp) at clinically relevant intestinal concentrations.

eksperimenti in vitro liecina, ka lumakaftors ir krūts vēža rezistences proteīna (breast cancer resistance protein – bcrp) substrāts.
in vitro experiments show that lumacaftor is a substrate for breast cancer resistance protein (bcrp).

apiksabāns ir transportolbaltumvielu, p-gp un krūts vēža rezistences proteīna (breast cancer resistance protein – bcrp) substrāts.
apixaban is a substrate of transport proteins, p-gp and breast cancer resistance protein (bcrp).

arī ar multirezistenci saistītais proteīns 1 (multidrug resistance protein 1; mdr1) spēj transportēt mfs, taču tas šķietami iesaistīts tikai uzsūkšanās procesā.
multidrug resistance protein 1 (mdr1) is also able to transport mpa, but its contribution seems to be confined to the absorption process.

sonidegibs ir arī krūts vēža rezistences proteīna jeb bcrp (breast cancer resistance protein) inhibitors (tā ik50 ir aptuveni 1,5 µm).
sonidegib is also a breast cancer resistance protein (bcrp) inhibitor (ic50 ~1.5µm).

eiropas savienība (es) atzīmē nolīgumu starp kdr un ugandu pagarināt 14. decembrī uzsākto kopīgo militāro darbību pret tā kunga pretošanās armiju ( lord’s resistance
the european union (eu) takes note of the agreement between the drc and uganda to extend the joint military action against the lord's resistance army (lra), which started on december 14.

ietekme uz bcrp (breast cancer resistance protein – krūts vēža rezistences proteīnu) un /vai organiskiem anjonu transportētājpolipeptīdu b1 un b3 (oatp1b1/b3) substrātiem
effect on bcrp (breast cancer resistance protein) and /or organic anion transporting polypeptide b1 and b3 (oatp1b1/b3) substrates